V
32.98
-0.77 (-2.28%)
| Previous Close | 33.75 |
| Open | 33.78 |
| Volume | 2,870,089 |
| Avg. Volume (3M) | 6,488,984 |
| Market Cap | 3,770,841,856 |
| Price / Book | 3.94 |
| 52 Weeks Range | |
| Earnings Date | 22 Oct 2025 |
| Diluted EPS (TTM) | -1.54 |
| Total Debt/Equity (MRQ) | 0.11% |
| Current Ratio (MRQ) | 25.86 |
| Operating Cash Flow (TTM) | -152.54 M |
| Levered Free Cash Flow (TTM) | -102.10 M |
| Return on Assets (TTM) | -14.99% |
| Return on Equity (TTM) | -19.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Viking Therapeutics, Inc. | Bearish | Mixed |
AIStockmoo Score
2.4
| Analyst Consensus | 4.0 |
| Insider Activity | 3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 2.40 |
|
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.15% |
| % Held by Institutions | 70.06% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 125.00 (BTIG, 279.02%) | Buy |
| Median | 102.00 (209.28%) | |
| Low | 75.00 (JP Morgan, 127.41%) | Buy |
| Average | 102.00 (209.28%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 31.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 29 Oct 2025 | 106.00 (221.41%) | Buy | 35.22 |
| JP Morgan | 24 Oct 2025 | 75.00 (127.41%) | Buy | 34.42 |
| Morgan Stanley | 23 Oct 2025 | 102.00 (209.28%) | Buy | 33.92 |
| HC Wainwright & Co. | 29 Sep 2025 | 102.00 (209.28%) | Buy | 25.81 |
| 19 Aug 2025 | 102.00 (209.28%) | Buy | 24.36 | |
| BTIG | 22 Sep 2025 | 125.00 (279.02%) | Buy | 26.25 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LIAN BRIAN | 35.93 | 34.93 | 31,095 | 1,156,232 |
| MANCINI MARIANNA | 35.93 | 34.93 | 4,932 | 183,392 |
| ROWLAND CHARLES A JR | 35.93 | 35.93 | 0 | 0 |
| ZANTE GREG | 35.93 | 34.93 | 4,932 | 183,392 |
| Aggregate Net Quantity | 40,959 | |||
| Aggregate Net Value ($) | 1,523,016 | |||
| Aggregate Avg. Buy ($) | 35.93 | |||
| Aggregate Avg. Sell ($) | 35.18 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ZANTE GREG | Officer | 28 Oct 2025 | Sell (-) | 6,185 | 34.93 | 216,042 |
| LIAN BRIAN | Officer | 28 Oct 2025 | Sell (-) | 38,989 | 34.93 | 1,361,886 |
| MANCINI MARIANNA | Officer | 28 Oct 2025 | Sell (-) | 6,185 | 34.93 | 216,042 |
| ZANTE GREG | Officer | 27 Oct 2025 | Acquired (+) | 11,117 | 35.93 | 399,434 |
| LIAN BRIAN | Officer | 27 Oct 2025 | Acquired (+) | 70,084 | 35.93 | 2,518,118 |
| ROWLAND CHARLES A JR | Director | 27 Oct 2025 | Acquired (+) | 60,000 | 35.93 | 2,155,800 |
| ROWLAND CHARLES A JR | Director | 27 Oct 2025 | Sell (-) | 60,000 | 35.93 | 2,155,800 |
| MANCINI MARIANNA | Officer | 27 Oct 2025 | Acquired (+) | 11,117 | 35.93 | 399,434 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |